![Gregor Klieber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Gregor Klieber worked at AlpenBank AG from 2006 to 2022 as the Head of Portfolio Management.
Precedenti posizioni note di Gregor Klieber
Società | Posizione | Fine |
---|---|---|
AlpenBank AG
![]() AlpenBank AG Investment ManagersFinance Part of Alpen Privatbank AG, AlpenBank AG is an Austrian company that focuses on chronic heart disease called hypertrophic cardiomyopathy (HCM). Founded in 1983, the company is based in Innsbruck, Austria. HCM is a serious heart condition that affects the heart muscle, causing the walls of the heart to become thicker than they should be. This excessive thickening can cause the heart to become more stiff, leaving less room for blood to fill the heart. As a result, those with HCM may experience fatigue, a fast heartbeat, chest pain, breathing problems, or light-headedness which may interfere with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risk of atrial fibrillation (irregular heartbeat), stroke, heart failure, and in rare cases, sudden cardiac death. | Direttore degli Investimenti | 11/01/2022 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
AlpenBank AG
![]() AlpenBank AG Investment ManagersFinance Part of Alpen Privatbank AG, AlpenBank AG is an Austrian company that focuses on chronic heart disease called hypertrophic cardiomyopathy (HCM). Founded in 1983, the company is based in Innsbruck, Austria. HCM is a serious heart condition that affects the heart muscle, causing the walls of the heart to become thicker than they should be. This excessive thickening can cause the heart to become more stiff, leaving less room for blood to fill the heart. As a result, those with HCM may experience fatigue, a fast heartbeat, chest pain, breathing problems, or light-headedness which may interfere with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risk of atrial fibrillation (irregular heartbeat), stroke, heart failure, and in rare cases, sudden cardiac death. | Finance |
- Borsa valori
- Insiders
- Gregor Klieber